Skip to main content

Table 9 (abstract O34). Incremental cost-effectiveness ratio (ICER) using prices of biosimilars in treatment of JIA

From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one

Treatment

Incremental Costs, €

Incremental QALYs

ICER estimate €/Qaly

COMBO vs MTX

-2918

0.072

dominanta

aTNF vs combo

7627

0.023

331 609

aTNF vs MTX

4926

0.095

51 853

  1. QALY Quality-Adjusted Life-Year
  2. aless costly and more effective treatment option